首页 | 本学科首页   官方微博 | 高级检索  
     


Long-term outcomes of pexidartinib in tenosynovial giant cell tumors
Authors:Hans Gelderblom MD  Andrew J. Wagner MD  PhD  William D. Tap MD  Emanuela Palmerini MD  PhD  Zev A. Wainberg MD  Jayesh Desai MBBS  John H. Healey MD  Michiel A. J. van de Sande MD  PhD  Nicholas M. Bernthal MD  Eric L. Staals MD  PhD  Charles G. Peterfy MD  PhD  Anna Maria Frezza MD  Henry H. Hsu MD  Qiang Wang PhD  Dale E. Shuster PhD  Silvia Stacchiotti MD
Affiliation:1. Leiden University Medical Center, Leiden, the Netherlands;2. Dana-Farber Cancer Institute, Boston, Massachusetts;3. Memorial Sloan Kettering Cancer Center, New York, New York

Weill Cornell Medical College, New York, New York;4. IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy;5. David Geffen School of Medicine, University of California Los Angeles, Santa Monica, California;6. Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;7. Memorial Sloan Kettering Cancer Center, New York, New York;8. Spire Sciences, Inc, Boca Raton, Florida;9. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;10. Plexxikon, Berkeley, California;11. Daiichi Sankyo, Inc, Basking Ridge, New Jersey

Abstract:
Keywords:efficacy  long term  pexidartinib  pooled analysis  safety  tenosynovial giant cell tumor (TGCT)  tumor response
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号